New Monoclonal Antibody Nebokitug Shows Promise for Rare Liver Disease PSC

A new monoclonal antibody, nebokitug, has demonstrated safety and potential efficacy in treating Primary Sclerosing Cholangitis (PSC), a rare liver disease. Phase 2 trial results indicate it reduces inflammation and fibrosis.

• Nebokitug, a new monoclonal antibody, targets Primary Sclerosing Cholangitis (PSC).
• Phase 2 trial showed nebokitug to be safe and well-tolerated in patients.
• Treatment demonstrated potential in reducing liver fibrosis and inflammation.
• Research led by UC Davis Health, published in American Journal of Gastroenterology.
• Nebokitug works by blocking the CCL24 protein, crucial for inflammation.

Read the full story on Quick Digest.